AOD 9604 vs Retatrutide: What's the Difference?

AOD 9604 and retatrutide are both discussed as weight-loss compounds, but they are not really competitors. AOD 9604 is a synthetic fragment of human growth hormone that failed to beat placebo in late-stage human trials, while retatrutide is an investigational triple-receptor agonist that produced roughly 24% weight loss in a Phase 2 trial. Neither compound is FDA-approved for weight loss in the United States.

That difference in evidence matters. One is a small peptide with dated trial data and a failed Phase 3 program; the other is a next-generation injectable still working through Phase 3 testing. Here is a plain-English breakdown of how they compare on mechanism, dosing, side effects, and legal status.

What Is AOD 9604?

AOD 9604 is a modified fragment of human growth hormone, corresponding to the C-terminal portion of the molecule (often described as amino acids 176–191). Because it does not bind the growth hormone receptor, it does not raise IGF-1 levels the way full HGH does, and it does not appear to affect blood sugar or growth.

Researchers developed the peptide to stimulate lipolysis (fat breakdown) and inhibit lipogenesis (fat storage). Early animal work looked promising, and the compound entered human obesity trials in the 2000s through Metabolic Pharmaceuticals.

• Mechanism: A growth hormone fragment that acts on fat metabolism rather than growth signaling
• Route: Subcutaneous injection, commonly reported at 250–500 mcg per day in community protocols; trial protocols used higher daily doses
• Human evidence: A Phase 2b trial suggested modest weight loss, but the follow-up Phase 3 trial failed to show a meaningful advantage over placebo
• FDA status: Not approved for any human use

Much of the current interest comes from forum posts and aod 9604 reviews written by users rather than from controlled research. Products sold online are usually labeled as research chemicals, which is a legal gray area, not an approval.

What Is Retatrutide?

Retatrutide (development code LY3437943) is an investigational drug from Eli Lilly that activates three hormone receptors at once: GLP-1, GIP, and glucagon. The GLP-1 and GIP components drive appetite suppression and better glucose handling, while the glucagon component adds direct energy expenditure.

In a Phase 2 trial published in the New England Journal of Medicine in 2023, adults with obesity who received 12 mg weekly lost an average of about 24% of their body weight over 48 weeks. That ranks among the largest weight-loss effects reported for any investigational agent.

• Mechanism: Triple agonist at the GLP-1, GIP, and glucagon receptors
• Route: Once-weekly subcutaneous injection
• Human evidence: Randomized Phase 2 trial with substantial weight loss; Phase 3 TRANSCEND program ongoing
• FDA status: Not approved; available only to clinical trial participants

The most common side effects in trials were gastrointestinal: nausea, vomiting, diarrhea, and constipation, mostly during dose escalation. Small increases in heart rate were also observed.

AOD 9604 vs Retatrutide: Side-by-Side Comparison

Feature	AOD 9604	Retatrutide
Compound type	hGH fragment peptide	Triple hormone receptor agonist
Primary target	Fat breakdown and fat storage	Appetite, glucose, and energy expenditure
Administration	Daily subcutaneous injection	Weekly subcutaneous injection
Human weight-loss data	Modest at best; Phase 3 missed its endpoint	About 24% body weight lost at 48 weeks on 12 mg
Common reported side effects	Injection-site reactions, headache, fatigue	Nausea, vomiting, diarrhea, constipation
Regulatory status (US)	Not approved; widely sold as a research chemical	Not approved; investigational in Phase 3
Evidence quality	Limited, dated, and mixed	Strong Phase 2 data; Phase 3 results pending

The table makes the core trade-off clear. AOD 9604 offers a gentler side-effect profile with weak results, while retatrutide offers much larger weight loss with more gastrointestinal burden.

How People Compare and Stack Them

Because the two compounds work through unrelated pathways, some users ask about aod 9604 and retatrutide together. No human trial has tested that combination, so any claimed synergy is speculation. The same is true of stacking a growth hormone fragment with other peptides, which is why comparisons such as aod 9604 vs hgh frag 176-191 and sermorelin vs aod 9604 come up so often in forums.

Others compare AOD 9604 with approved GLP-1 drugs instead. Discussions about aod 9604 with tirzepatide usually describe adding the peptide on top of a prescription, but that combination has not been studied and could make side effects harder to track.

If the goal is clinically proven weight loss, approved medications such as tirzepatide (Zepbound) and semaglutide (Wegovy) have far more human data than AOD 9604. If the goal is research interest, retatrutide is the more compelling molecule, and also the one with more unknowns.

Safety, Legality, and What to Watch For

Neither AOD 9604 nor retatrutide is FDA-approved for human use in the United States. AOD 9604 is frequently sold online as a research chemical or included in unapproved dietary supplements, and the FDA has warned consumers about peptides marketed this way.

Retatrutide cannot legally be obtained with a prescription because it remains investigational. Vials sold as retatrutide outside a clinical trial are unverified, and their identity, purity, and sterility are not guaranteed.

Anyone considering either compound should talk with a licensed healthcare professional first, especially people with a history of pancreatitis, gallbladder disease, thyroid cancer, or eating disorders. Self-dosing research peptides carries real risks, including contamination, dosing errors, and unknown drug interactions.

Bottom Line

Retatrutide and AOD 9604 are not close substitutes. Retatrutide is a triple agonist with some of the strongest weight-loss data of any investigational drug, but it is not yet approved and is only available through clinical trials. AOD 9604 is a growth hormone fragment whose late-stage obesity trial failed, and it is not approved for human use.

For most people searching AOD 9604 vs retatrutide, the practical answer is that approved GLP-1 and GIP/GLP-1 medications currently offer the best-documented results, and any use of unapproved peptides should be discussed with a clinician.

COMMON QUESTIONS

Frequently Asked Questions

Is retatrutide FDA approved?

No. Retatrutide is an investigational drug and has not been approved by the FDA for weight loss or any other indication. It is available only to participants in Eli Lilly's Phase 3 TRANSCEND clinical trials. Approved options in a similar class include tirzepatide (Zepbound) and semaglutide (Wegovy).

Does AOD 9604 actually burn fat?

The human data are weak. AOD 9604 showed only modest weight loss in a Phase 2b trial, and the larger Phase 3 trial did not show a significant benefit over placebo. Most fat-burning claims come from animal studies and user anecdotes rather than controlled human research.

Can you take AOD 9604 and retatrutide together?

There is no human research on combining AOD 9604 with retatrutide, so the safety and effectiveness of that stack are unknown. Because retatrutide is only available through clinical trials, using both outside a supervised study is not advisable. Speak with a licensed healthcare professional before starting either compound.